July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Evaluation of XEN implant in the surgical management of glaucoma: about 24 cases, a preliminary study
Author Affiliations & Notes
  • Hussam El Chehab
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Emilie Agard
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Antoine Levron
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Mayeul Chaperon
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Roman Chudzinski
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Corinne Dot
    Ophthalmology, Desgenettes Hospital, Lyon, France
  • Footnotes
    Commercial Relationships   Hussam El Chehab, None; Emilie Agard, None; Antoine Levron, None; Mayeul Chaperon, None; Roman Chudzinski, None; Corinne Dot, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3737. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hussam El Chehab, Emilie Agard, Antoine Levron, Mayeul Chaperon, Roman Chudzinski, Corinne Dot; Evaluation of XEN implant in the surgical management of glaucoma: about 24 cases, a preliminary study. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3737. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Recently, minimally invasive glaucoma surgery (MIGS) techniques have been developed to reduce the complications of conventional filtering surgeries that can affect the functional prognosis of our patients. The purpose of our study is to present the results at 1 year in patients who had surgery with XEN® Implant (Allergan Inc., Irvine, CA, USA) in combination with 5-Fluorouracil.

Methods : We included, retrospectively, all patients who had XEN surgery (standalone or combined with cataract surgery) in our department. Patients underwent a subconjunctival injection of 0.01mL of 5-Fluorouracil at the site of XEN implantation at the beginning of the procedure. We collected retrospectively: intra-ocular pression (IOP), number IOP lowering treatment, per and postoperative complications and needling procedure during postoperative follow-up. Data were collected before, Day 1, Month 1, 6, 9 and 12 after the procedure.

Results : We included 24 eyes of 23 patients. The mean age is 76.6 +/- 8.3years. The mean MD is -10.5dB +/- 7. The IOP before procedure is 19.3mmHg +/- 4.9. At 12 months after the procedure, IOP is 13.8mmHg +/- 6.1 (-28.3% compared to initial IOP). The needling rate is 54.4%. It is realized 2.3 +/- 1.8months after the procedure. Visual acuity remained stable during follow-up. The number of IOP lowering treatments decreases from 3.3 +/- 0.8 treatments before the procedure to 1 +/- 1.4 treatments at 12 months after the procedure. The complications encountered are related to postoperative hypotonia and are transient. Two patients require a surgical management, the first patient in the fith post-operative days for a persistent athalamia and the second patient later (5 months post-op) for a partial migration of the implant into the anterior chamber.

Conclusions : This study reports the efficacy of the XEN® implant (Allergan Inc., Irvine, CA, USA) with 5-Fluorouracil in the surgical management of glaucoma. The needling rate seems to be higher than other studies of the literature. These results must be confirmed by a series with more patients and a larger sample.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.